ESMO 2010 - Dr. Ross Camidge, MD discusses Clinical Activity of Crizotinib (PF-02341066), in ALK-Positive Patients with Non-Small Cell Lung Cancer (NSCLC)

esmo2010 has 15 videos Subscribe Here

Loading........

4,211views

Description:Dr. Ross Camidge, MD discusses Clinical Activity of Crizotinib (PF-02341066), in ALK-Positive Patients with Non-Small Cell Lung Cancer (NSCLC)

Shared By : esmo2010
Posted on : 10/10/10
Added : 3 years ago
Category : Lung Oncology

Tags: Dr. Ross Camidge, MD discusses Clinical Activity of Crizotinib (PF-02341066), in ALK-Positive Patients with Non-Small Cell Lung Cancer (NSCLC)

More From esmo2010

10:05

Rare Cancer Press Briefing - Part 4

by: esmo2010
1957 views | 3 years ago

11:03

Rare Cancer Press Briefing - Part 3

by: esmo2010
1889 views | 3 years ago

11:16

Rare Cancer Press Briefing - Part 1

by: esmo2010
2030 views | 3 years ago

07:44

Rare Cancers Press Briefing - Part 5

by: esmo2010
2034 views | 3 years ago

06:31

Rare Cancer Press Briefing - Part 2

by: esmo2010
1971 views | 3 years ago

Please help us provide the best service.

I'm intersted in oncology videos because I'm a...

No Thanks(close window)

Membership has its privileges.

I already have an account log me in.

Username:
Password:
Remember me


Forgot your password?
Not Yet a Member? Sign up for FREE here!

ESMO 2010 - Dr. Ross Camidge, MD discusses Clinical Activity of Crizotinib (PF-02341066), in ALK-Positive Patients with Non-Small Cell Lung Cancer (NSCLC)

Recommended

More From esmo2010